Risk of S. aureus Bacteremia Up in Patients on Glucocorticoids

This article originally appeared here.
Share this content:
Risk of <i>S. aureus</i> Bacteremia Up in Patients on Glucocorticoids
Risk of S. aureus Bacteremia Up in Patients on Glucocorticoids

FRIDAY, June 10, 2016 (HealthDay News) -- Patients taking systemic glucocorticoids are at higher risk for community-acquired Staphylococcus aureus bacteremia (CA-SAB), according to research published online June 8 in Mayo Clinic Proceedings.

Jesper Smit, M.D., of Aarhus University Hospital in Denmark, and colleagues reviewed the medical records of 29,017 patients in Denmark and found that those who used systemic glucocorticoids were 2.5 times more likely than non-users to develop CA-SAB (adjusted odds ratio, 2.48).

The researchers also found that CA-SAB risk rose along with the dose of the medicines given. Compared to non-users, those with a 90-day cumulative corticosteroid dose less than or equal to 150 mg had 2.42 times higher risk, but the risk was as high as 6.25 times greater for patients with a cumulative dose of more than 1,000 mg. Among patients with connective tissue disease or chronic lung disease, the risk of CA-SAB was highest in long-term glucocorticoid users. Among cancer patients, the risk was highest for new users of the drugs.

The findings are "a reminder for clinicians to weigh carefully the elevated risk against the potential beneficial effect of glucocorticoid therapy," Smit said in a Mayo news release.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

SABCS: Artificial Intelligence May Aid Doctors in Breast Cancer Care

SABCS: Artificial Intelligence May Aid Doctors in Breast ...

'Watson Oncology' agreed with doctors 90 percent of the time in many cases, researchers find

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

Devices reduce blood flow to hair follicles during chemotherapy treatments

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

Women on aromatase inhibitors exhibit less elasticity in their blood vessels

is free, fast, and customized just for you!

Already a member?

Sign In Now »